Trials / Completed
CompletedNCT01196559
Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer
A Phase II Study of Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Epithelial Ovarian/Fallopian Tube/ Primary Peritoneal Carcinoma.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- The Catholic University of Korea · Academic / Other
- Sex
- Female
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the objective response rate and safety in platinum-resistant epithelial ovarian/fallopian tube/primary peritoneal cancer patients treated with vinorelbine and gemcitabine combination chemotherapy.
Detailed description
Other objectives of this study are to evaluate Progression-free survival and measure CA-125 response rate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vinorelbine and Gemcitabine | Gmcitabine 1000㎎/㎡ mix in normal saline 100ml iv for 30min andVinorelbine 25㎎/㎡ mix in normal saline 50 ml iv for 5-10min on D1 and 8 every 21 days cycle |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2014-10-01
- Completion
- 2014-10-01
- First posted
- 2010-09-08
- Last updated
- 2015-02-18
Locations
4 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01196559. Inclusion in this directory is not an endorsement.